CARGO Therapeutics to Discontinue FIRCE-1 Phase 2 Study of Firi-cel; Advances Remaining Programs While Evaluating Strategic Options
January 29, 2025 16:05 ET
|
Cargo Therapeutics, Inc.
CARGO Therapeutics to Discontinue FIRCE-1 Phase 2 Study of Firi-cel; Advances Remaining Programs While Evaluating Strategic Options
CARGO Therapeutics Provides Corporate Update and Anticipated Milestones for 2025
January 10, 2025 08:00 ET
|
Cargo Therapeutics, Inc.
CARGO Therapeutics Provides Corporate Update and Anticipated Milestones for 2025
Marker Therapeutics Announces $16.1 Million Private Placement
December 19, 2024 08:06 ET
|
Marker Therapeutics
HOUSTON, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma
December 19, 2024 08:05 ET
|
Marker Therapeutics
APOLLO study investigating MT-601 in patients with relapsed lymphoma: 78% of patients achieved objective response rates, with 44.4% demonstrating complete response (CR) MT-601 was observed to be well...
Refractory Follicular Lymphoma Diagnostics Market Trends and Forecasts to 2029 - The Rise of Liquid Biopsy
December 17, 2024 14:13 ET
|
Research and Markets
Dublin, Dec. 17, 2024 (GLOBE NEWSWIRE) -- The "Refractory Follicular Lymphoma Diagnostics Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2019-2029F" report has been added to...
CARGO Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
December 17, 2024 08:00 ET
|
Cargo Therapeutics, Inc.
CARGO Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer
December 17, 2024 07:00 ET
|
Marker Therapeutics
HOUSTON, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium
December 10, 2024 08:30 ET
|
Marker Therapeutics
HOUSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit
November 26, 2024 11:00 ET
|
Marker Therapeutics
HOUSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 14, 2024 16:30 ET
|
Marker Therapeutics
HOUSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...